Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Fukuyzu Pharmaceutical Co., Ltd.
483
•Fukuyzu Pharmaceutical Co., Ltd.•January 19, 2024

Fukuyzu Pharmaceutical Co., Ltd. – FDA 483, Jan 19, 2024

Record Details

An FDA inspection conducted from January 15-19, 2024, at Fukuzyu Pharmaceutical Co., Ltd. in Toyama, Japan, identified several significant issues related to its Active Pharmaceutical Ingredient (API) manufacturing processes. The observations indicate a lack of robust quality control and data integrity, which are critical for ensuring product safety and efficacy.

Key violations include the quality unit's failure to conduct thorough investigations into out-of-specification results and critical deviations. For instance, investigations into high Pyrimethamine assay and residual solvent levels lacked scientific justification and adequate follow-up on potential impacts to other batches.

Furthermore, the company's cleaning procedures for shared production equipment were found to be insufficient, with apparent residue and particulates observed. Cleaning validation protocols failed to meet stability acceptance criteria for standard solutions, raising concerns about potential cross-contamination, especially between hazardous and non-hazardous substances.

The inspection also noted incomplete validation of analytical methods, specifically the in-house gas chromatography method used for releasing Pyrimethamine API. Crucially, controls over computerized systems and electronic records in the Quality Control laboratory were inadequate. A single administrator had unlimited ability to modify or delete electronic data, and one system lacked essential data integrity features like forced saving and audit trails, compromising the reliability and security of critical quality data.

Fukuzyu Pharmaceutical Co., Ltd. is expected to address these observations by implementing comprehensive corrective and preventive actions to ensure compliance with good manufacturing practices and safeguard product quality.

Company
Fukuyzu Pharmaceutical Co., Ltd.
Inspection date
January 19, 2024
Product type
drugs
Office
Baltimore District Office
Person
  • Nicholas L. Hunt (Senior CSO, Investigator)
View Company Profile

ID · ead9d25a-438f-4435-9b00-614c66e0f3ba

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Fukuyzu Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.